In:
Surgical Case Reports, Science Repository OU
Kurzfassung:
Tocilizumab is a monoclonal antibody against the interleukin-6 receptor. Gastrointestinal perforation has been associated with Tocilizumab treatment. In the absence of specific antiviral drugs, Tocilizumab is currently being used as a treatment option in patients with severe COVID-19 pneumonia. This is being based on the implication of interleukin-6 in the aberrant host immune response that characterizes the disease and initiates patients' lung damage. Herein we present the case of a cecal perforation in a patient treated with Tocilizumab for COVID-19. In such context, we expect that there may be an increase in the incidence of gastrointestinal perforation related to Tocilizumab.
Materialart:
Online-Ressource
ISSN:
2613-5965
,
2613-5965
DOI:
10.31487/j.SCR.2021.08.21
Sprache:
Unbekannt
Verlag:
Science Repository OU
Publikationsdatum:
2021